Product Datasheet

BMS-986365


Catalog No. **BP-00080** · CAS **2446928-30-7** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-11-12**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
PROTACs; Androgen Receptor	**Cancer**

Molecular formula	$C_{41}H_{45}F_3N_8O_5S$
Molecular weight	**818.9070**

STRUCTURE



DESCRIPTION

BMS-986365 (CC-94676) is a selective heterobifunctional ligand-directed degrader (LDD) targeting the androgen receptor (AR). BMS-986365 (CC-94676) demonstrated significant in vivo potency, degrading AR, inhibiting AR signaling, and inhibiting tumor growth in animal models of advanced prostate cancer.

BIOLOGICAL ACTIVITY

BMS-986365 (0.05-5 μM; 6 h) maintains low levels of AR protein despite increased AR transcript levels in VCaP and LNCaP cells[3].

BMS986365 (0.1-10 μM; 6-72 hours) inhibits AR target gene transcription and AR-dependent proliferation in VCaP and LNCaP cells[3].

BMS-986365 exhibits AR degradation potency in VCaP (ARWT amplified) cells with a GI50: 753 nM)[3].

BMS-986365 shows a difference in degradation potency in VCaP cells and LNCaP cells, with DC50 values of 7 nM and 29 nM, respectively[3].

BMS986365 potently inhibits androgen-stimulated proliferation of VCaP and LNCaP cells but showed little antiproliferative effect in 22Rv1 or PC3 cells[3].

BMS986365 inhibits R1881-stimulated proliferation of VCaP and LNCaP cells with GI50 values of 11 and 4 nM, respectively

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 100 mg/mL

REFERENCES

[1]. Xu S, et al. Abstract ND02: Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer[J]. Cancer Research, 2024, 84(7_Supplement): ND02-ND02.

[2]. Rathkopf DE, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2024 Sep 16:S0923-7534(24)04001-8.

[3]. Nayak S, et al. Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer. Clin Cancer Res. 2025 Aug 11.

[4]. Rathkopf D E, et al. First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)[J]. 2024.